CYP2D6 rs1057516309: Understanding Your Pharmacogenetic Profile

What each genotype means

What is the rs1057516309 Variant?

The rs1057516309 variant is a specific genetic change found within the CYP2D6 gene locus. In genomics, an rsID (reference SNP cluster ID) like rs1057516309 acts as a unique identifier for a specific location in the human genome where a single nucleotide polymorphism (SNP) or other variation may occur. The CYP2D6 gene is located on chromosome 22 and is highly polymorphic, meaning it contains a vast number of variations across different human populations. Because this region is complex, researchers often study specific variants to understand how they might alter the structure or expression of the resulting enzyme. Identifying this variant is part of the broader effort in pharmacogenomics to map how specific DNA sequences correlate with differences in how people metabolize drugs, which can ultimately influence the safety and efficacy of medical treatments.

The Role of the CYP2D6 Gene

The CYP2D6 gene encodes the cytochrome P450 2D6 enzyme, which is primarily expressed in the liver. This enzyme is responsible for the metabolism of approximately 20% to 25% of all clinically used medications, including antidepressants, antipsychotics, beta-blockers, and certain pain medications. Unlike many other enzymes in the P450 family, CYP2D6 is generally considered non-inducible, meaning its activity levels are largely determined by an individual's genetics rather than external factors like diet or other drugs. Because it processes such a wide array of common drugs, variations in the CYP2D6 gene can lead to significant differences in how quickly or slowly a person clears a medication from their system. This can result in either therapeutic failure if the drug is cleared too quickly, or an increased risk of side effects if the drug accumulates to toxic levels.

Research and Clinical Evidence

Research into CYP2D6 variants like rs1057516309 is categorized under pharmacogenomics, a field that examines how genetic makeup influences drug response. The evidence strength for many specific variants in this complex locus is often described as moderate, as researchers must account for the high degree of structural variation, including gene duplications and deletions, that characterize the CYP2D6 region. Studies often use in vitro assays to determine if a specific variant reduces, eliminates, or increases the catalytic activity of the enzyme. While some variants are well-characterized, others like rs1057516309 are part of ongoing investigations to determine their precise clinical impact. It is important to note that clinical guidelines, such as those from the Clinical Pharmacogenetics Implementation Consortium (CPIC), are typically based on the overall predicted phenotype—such as poor, intermediate, or ultrarapid metabolizer—rather than a single SNP alone.

Population Frequency and Diversity

The frequency of CYP2D6 variants is highly variable across different global populations. Genetic diversity in this gene is significant, with some alleles being common in specific ancestral groups while remaining rare or absent in others. For instance, certain decreased-function alleles are more prevalent in populations of African ancestry, while other variations are more common in European or Asian cohorts. Because of this variability, the prevalence of the rs1057516309 variant is not uniform, and its clinical relevance may differ depending on an individual's genetic background. Researchers continue to sequence diverse populations to better understand the full landscape of CYP2D6 variation, which is essential for developing equitable and accurate pharmacogenetic testing strategies that work for all patients regardless of their ancestry.

Navigating Genetic Information

Understanding your genetic variants can provide insights into your potential drug response, but this information should always be interpreted within a clinical context. A genetic test result is not a medical diagnosis, and it does not predict how you will react to every medication. Many factors, including age, liver function, kidney health, and other medications you may be taking, also influence drug metabolism. If you have received information about your CYP2D6 genotype, it is essential to discuss these results with your physician or a clinical pharmacist. They can help determine if your genetic profile warrants a change in medication or dosage. Never make changes to your prescribed treatment plan based on genetic data without professional medical guidance, as doing so could be harmful to your health.

Frequently asked questions

Sources & further reading

Related variants in CYP2D6